Table of Contents
- Trial overview
- Who can participate
- What is being studied
- Study phase and design
- Outcomes being measured
Trial overview
The available trial information shows one interventional study of Azd0305 in adults with multiple myeloma, a cancer of plasma cells in the bone marrow.[1] The study is authorised, is in Phase 1/2, and plans to enroll 292 participants.[1]
Who can participate
This trial is for adults with multiple myeloma.[1] The source data provided here does not list all inclusion and exclusion rules, so the full eligibility details are not shown in this summary.[1]
What is being studied
Researchers are studying Azd0305 alone and in combination with other cancer treatments.[1] The listed study drugs include pomalidomide taken by mouth and elranatamab given by subcutaneous injection, which means an injection under the skin.[1]
The main goal is to assess safety and tolerability and to find the Recommended Phase 2 Dose (RP2D) of Azd0305 in these treatment settings.[1] In simple terms, the study is trying to learn what dose may be suitable for later testing and whether the treatment can be given safely.[1]
Study phase and design
This is a Phase 1/2 study, which usually means the research starts by focusing on safety and dose, then moves toward early testing of how well the treatment may work.[1] The trial is also described as interventional, meaning participants receive a study treatment rather than only being observed.[1]
The trial title says it is designed to learn whether Azd0305 alone and with other cancer treatments is safe and works in adults with multiple myeloma.[1] This tells patients that the study is not only about safety, but also about early signs of benefit.[1]
Outcomes being measured
The main outcome in the early dose-escalation part is dose-limiting toxicities, which are side effects serious enough to stop the dose from being increased.[1] The study also measures the incidence and severity of adverse events and serious adverse events, meaning how often unwanted health problems happen and how bad they are.[1]
The brief summary says the study is also trying to determine the RP2D of Azd0305 as a single treatment and in combination with other anticancer agents.[1] Module-specific endpoints are mentioned in the source, but they are not listed in the provided data.[1]
Key terms explained
Multiple myeloma is a cancer that affects plasma cells, which are part of the immune system.[1] Subcutaneous injection means a shot given under the skin, and intravenous infusion means a medicine given through a vein.[1] Oral treatment means a medicine taken by mouth.[1]
Adverse events are any unwanted health problems seen during a study, while serious adverse events are the more severe ones, such as those that are life-threatening or need hospital care.[1]
